Molecular Subtype
HER2-Positive Gastric Adenocarcinoma
CI-CAN-00007796Explore in graph →
15 active trials
- NCIt
- C227256
Loading cancer entity…
Molecular Subtype
CI-CAN-00007796Explore in graph →
Clinical trials
43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors |
| unknown |
| Phase 2 |
| 72 |
| Karolinska University HospitalOTHER |
| 1 |
| Nov 30, 2022 |
| clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT05270889 | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial | unknown | Phase 2 | 50 | Yonsei UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05165602 | Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System | unknown | — | 30 | Peking UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | unknown | Phase 2 | 35 | Shengjing HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT04520295 | ctDNA Screening in Advanced HER2 Positive Gastric Cancer | unknown | — | 100 | Ruijin HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT02378389 | Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer | unknown | Phase 1 | 28 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 4, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Dec 18, 2024source: clinicaltrials